- Approval Id
- 4607d9944e4e868b
- Drug Approval Emc Name
- Colchicine 500 microgram tablets
- Drug Name
- Colchicine 500 microgram tablets
- Company Address
- Morningside House, Unit C Harcourt Way, Meridian Business Park, Leicester, LE19 1WP
- Company Website
- http://www.morningsidehealthcare.com
- Company Telephone
- +44 (0)116 204 5950
- Company Medical Info Direct Line
- +44 (0)116 478 0322
- Company Medical Info Email
- medicalenquiry@morningsidehealthcare.com
- Company Customer Care Direct Line
- +44 (0)116 204 5950
- Company Stock Availability
- +44 (0)1509 217 705
- Atc Code
- M04AC01
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Morningside Healthcare Ltd
Unit C, Harcourt Way
Leicester, LE19 1WP, UK
- Authorisation Number
- PL 20117/0262
- Authorisation Date
- 16/06/2016
- Instruction Authorisation Holder
- Morningside Healthcare Ltd
Unit C, Harcourt Way
Leicester, LE19 1WP, UK
- Instruction Authorisation Number
- PL 20117/0262
- Instruction Authorisation Date
- 16/06/2016
- Instruction Composition
- Each tablet contains 500 micrograms of colchicine (as colchicine sesquihydrate).
Excipient(s) with known effect: each tablet contains 46 mg lactose monohydrate equivalent to 43.7 mg of lactose anhydrous (see section 4.4).
For the full list of excipients, see 6.1.
- Instruction Dosage Form
- Tablet - oral use.
White to off-white coloured, circular biconvex uncoated tablet with “C5” debossed on one side and plain on the other side with diameter of 5.5 mm.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
\*Adults\*
• Treatment of acute gout.
• Prophylaxis of gout attack during initiation of therapy with allopurinol and uricosuric drugs.
\*\*Paediatric Population:\*\*
Colchicine is indicated in Familial Mediterranean Fever for prophylaxis of attacks and prevention of amyloidosis.4.2 Posology and method of administration
Posology
\*Adults\*
\*Treatment of acute gout attack:\*
1 mg (2 tablets) to start followed by 500 micrograms (1 tablet) after1 hour.
No further tablets should be taken for 12 hours.
After 12 hours, treatment can resume if necessary with a maximum dose of500 micrograms (1 tablet) every 8 hours until symptoms are relieved.\*.\* The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken.
No more than6 mg (12 tablets) should be taken as a course of treatment.
After completion of a course, another course should not be started for at least three days (72 hours).
\*Prophylaxis of gout attack during initiation of therapy with allopurinol and uricosuric drugs:\*
500 micrograms twice daily.
The treatment duration should be decided after factors such as flare frequency, gout duration and the presence and size of tophi have been assessed.
\*Patients with renal impairment\*
Use with caution in patients with mild renal impairment. For patients with moderate renal impairment, reduce dose or increase interval between doses. Such patients should be carefully monitored for adverse effects of colchicine (see also section 5.2).
For patients with severe renal impairment, see section 4.3.
\*Patients with hepatic impairment\*
Use with caution in patients with mild/moderate hepatic impairment. Such patients should be carefully monitored for adverse effects of colchicine.
For patients with severe hepatic impairment, see section 4.3.
\*Paediatric population\*
Familial Mediterranean fever.
For paediatric use, colchicine should only be prescribed under the supervision of a medical specialist with the necessary knowledge and experience.
A starting dose should be administered orally based on age:
0.5 mg / day in children less than 5 years of age (1 tablet);
1 mg / day in children from 5 to 10 years of age (2 tablets);
1.5 mg / day in children over 10 years (3 tablets).
The dose could be given as a single dose or doses higher than 1 mg / day could be divided and given twice daily.
Colchicine dosage should be increased in a stepwise fashion (e.g., 0.25mg/step) up to a maximum of 2mg/day (four tablets a day) to control disease in patients who do not clinically respond to the standard dosage. Any increase of the daily dose should be monitored closely for adverse effects. In children with amyloid nephropathy, higher daily doses up to 2mg/day might be needed. Careful monitoring is needed in the presence of impaired renal or liver function. For these patients, the starting dose should be reduced by 50% (e.g. ≤ 1mg/day).
\*Elderly\*
Use with caution.
Method of Administration
For Oral administration
Tablets should be swallowed whole with a glass of water.
In certain circumstances, it may not be possible to administer the tablets orally, please refer to recommendations in section 6.6 for administration as an oral dispersion. These recommendations are also suitable for administration via nasogastric tube or percutaneous endoscopic gastrostomy (PEG) tube.4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Patients with blood dyscrasias
• Pregnancy
• Breastfeeding
• Women of childbearing potential unless using effective contraceptive measures
• Patients with severe renal impairment
• Patients with severe hepatic impairment
• Colchicine should not be used in patients undergoing haemodialysis since it cannot be removed by dialysis or exchange transfusion.
• Colchicine is contraindicated in patients with renal or hepatic impairment who are taking a P-glycoprotein (P-gp) inhibitor or a strong CYP3A4 inhibitor (see section 4.5)4.4 Special warnings and precautions for use
Colchicine is potentially toxic so it is important not to exceed the dose prescribed by a physician with the necessary knowledge and experience.
Colchicine has a narrow therapeutic window. The administration should be discontinued if toxic symptoms such as nausea, vomiting, abdominal pain, diarrhoea occur.
Colchicine may cause severe bone marrow depression (agranulocytosis, aplastic anaemia, thrombocytopenia). The change in blood counts may be gradual or very sudden. Aplastic anaemia in particular has a high mortality rate. Periodic checks of the blood picture are essential.
If patients develop signs or symptoms that could indicate a blood cell dyscrasia, such as fever, stomatitis, sore throat, prolonged bleeding, bruising or skin disorders, treatment with colchicine should be immediately discontinued and a full haematological investigation should be conducted straight away.
Caution is advised in case of:
• liver or renal impairment• cardiovascular disease• gastrointestinal disorders• elderly and debilitated patients• patients with abnormalities in blood counts
Patients with liver or renal impairment should be carefully monitored for adverse effects of colchicine (see section 5.2).
Co-administration with P-gp inhibitors and/or moderate or strong CYP3A4 inhibitors will increase the exposure to colchicine, which may lead to colchicine-induced toxicity including fatalities. If treatment with a P-gp inhibitor or a moderate or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, a reduction in colchicine dosage or interruption of colchicine treatment is recommended (see section 4.5).
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
Colchicine is a substrate for both CYP3A4 and the transport protein P-gp. In the presence of CYP3A4 or P-gp inhibitors, the concentrations of colchicine in the blood increase. Toxicity, including fatal cases, have been reported during concurrent use of CYP3A4 or P-gp inhibitors such as macrolides (clarithromycin and erythromycin), ciclosporin, ketoconazole, itraconazole, voriconazole, HIV protease inhibitors, calcium channel blockers (verapamil and diltiazem) and disulfiram (see section 4.4).
Colchicine is contraindicated in patients with renal or hepatic impairment who are taking a P-gp inhibitor (e.g. ciclosporin, verapamil or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketoconazole) (see section 4.3).
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with a P-gp inhibitor or strong CYP3A4 inhibitor is required (see section 4.4).
A 4-fold reduction in colchicine dosage is recommended when co-administered with a P-gp inhibitor and/or a strong CYP3A4 inhibitor. A 2-fold reduction in colchicine dosage is recommended when co-administered with a moderate CYP3A4 inhibitor.
The magnitude of interactions with strong and moderate CYP3A4 inhibitors as well as with P-gp inhibitors from performed \*in vivo\* studies is summarised in the table below:
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Single dose of 0.6 mg colchicine without or with:\*\* | \*\*Number of subjects\*\* | \*\*% change in colchicine pharmacokinetic parameters\*\* | | \*\*Guidance for dose reduction:\*\* |
| \*\*Cmax\*\* | \*\*AUCo-t\*\* |
| \*\*Strong CYP3A4 inhibitors\*\* Clarithromycin 250 mg twice daily for 7 days Ketoconazole 200 mg twice daily for 5 days Ritonavir 100 mg twice daily for 5 days | N=23 N=24 N=18 | 297 190 267 | 339 287 345 | 4-fold Acute gout regimen to be repeated no earlier than 3 days. |
| \*\*Moderate CYP3A4 inhibitors\*\* Verapamil ER 240 mg once daily for 5 days Diltiazem ER 240 mg once daily for 7 days Grapefruit juice 240 ml twice daily for 4 days | N=24 N=20 N=21 | 130 129 93 | 188 177 95 | 2-fold Acute gout regimen to be repeated no earlier than 3 days. |
| \*\*Potent P-gp inhibitors\*\* Cyclosporin 100 mg single dose | N=23 | 324 | 317 | 4-fold Acute gout regimen to be repeated no earlier than 3 days. |
Given the nature of the side effects, caution is advised with concomitant administration of drugs that can affect the blood count or have a negative effect on hepatic and/or renal function.
In addition, substances such as cimetidine and tolbutamide reduce metabolism of colchicine and thus plasma levels of colchicine increase.
Grapefruit juice may increase plasma levels of colchicine. Grapefruit juice should therefore not be taken together with colchicine.
Reversible malabsorption of cyanocobalamin (vitamin B12) may be induced by an altered function of the intestinal mucosa.
The risk of myopathy and rhabdomyolysis is increased by a combination of colchicine with statins, fibrates, ciclosporin or digoxin.4.6 Fertility, pregnancy and lactation
Fertility
Colchicine administration in animals induces significant reductions in fertility.
Pregnancy
Colchicine is genotoxic in vitro and in vivo, and is teratogenic in animal studies (see section 5.3). Colchicine is therefore contraindicated in pregnancy (see section 4.3).
Women of childbearing potential have to use effective contraception during treatment.
Women should be advised not to become pregnant whilst taking Colchicine and for nine months following the cessation of therapy and should use barrier or other non-hormonal contraceptive methods if sexually active. Premenopausal patients must be carefully examined before treatment to exclude pregnancy. Women should be appraised of the potential risks to the foetus, should they become pregnant whilst taking medicine or within nine months of cessation of therapy.
Breastfeeding
Colchicine is excreted in breast milk. Therefore, use of colchicine is contraindicated in women who are breastfeeding (see section 4.3).4.7 Effects on ability to drive and use machines
No details are available regarding the influence of colchicine on the ability to drive and use machines. However, the possibility of drowsiness and dizziness should be taken into account.4.8 Undesirable effects
The following adverse reactions have been observed.
The frequencies are listed under one of the following classifications:
Very common > 1/10
Common > 1/100 and < 1/10Uncommon > 1/1,000 and < 1/100Rare>1/10,000 and < 1/1,000Very rare < 1/10,000
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
\*Not known\*: bone marrow depression with agranulocytosis, aplastic anaemia and thrombocytopenia.
Nervous system disorders
\*Not known\*: peripheral neuritis, neuropathy.
Gastrointestinal system disorders
\*Common\*: abdominal pain, nausea, vomiting and diarrhoea.
\*Not known\*: gastrointestinal haemorrhage.
Hepatobiliary disorders
\*Not known\*: Hepatotoxicity
Skin and subcutaneous tissue disorders
\*Not known\*: alopecia, rash.
Musculoskeletal and connective tissue disorders
\*Not known\*: myopathy and rhabdomyolysis.
Renal and urinary disorders
\*Not known\*: renal damage.
Reproductive system and breast disorders
\*Not known\*: amenorrhoea, dysmenorrhoea, oligospermia, azoospermia.
\*\*Reporting of suspected adverse reactions:\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Colchicine has a narrow therapeutic window and is extremely toxic in overdose. Patients at particular risk of toxicity are those with renal or hepatic impairment, gastro-intestinal or cardiac disease and patients at extremes of age.
Following colchicine overdose, all patients, even in the absence of early symptoms, should be referred for immediate medical assessment.
\*Clinical:\*
Symptoms of acute overdosage may be delayed (3 hours on average): nausea, vomiting, abdominal pain, haemorrhagic gastroenteritis, volume depletion, electrolyte abnormalities, leukocytosis, and hypotension in severe cases. The second phase with life threatening complications develops 24 to 72 hours after drug administration: multisystem organ dysfunction, acute renal failure, confusion, coma, ascending peripheral motor and sensory neuropathy, myocardial depression, pancytopenia, dysrhythmias, respiratory failure, consumption coagulopathy. Death is usually a result of respiratory depression and cardiovascular collapse. If the patient survives, recovery may be accompanied by rebound leukocytosis and reversible alopecia starting about one week after the initial ingestion.
\*Treatment:\*
No antidote is available.
Elimination of toxins by gastric lavage within one hour of acute poisoning.
Consider oral activated charcoal in adults who have ingested more than 0.1mg/kg bodyweight within 1 hour of presentation and in children who have ingested any amount within 1 hour of presentation. Haemodialysis has no efficacy (high apparent distribution volume).
Close clinical and biological monitoring in hospital environment.
Symptomatic and supportive treatment: control of respiration, maintenance of blood pressure and circulation, correction of fluid and electrolytes imbalance.
The lethal dose varies widely (7 - 65 mg single dose) for adults but is generally about 20 mg.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: drugs for gout, with no effect on uric acid metabolism. ATC code: M04AC01
In the AGREE (Acute Gout Flare Receiving Colchicine Evaluation) study low- and high-dose colchicine were compared using a randomized, placebo-controlled design. The high-dose prolonged colchicine regimen (4.8 mg total over 6 hours) was compared with a placebo and a low-dose abbreviated regimen (1.8 mg total over 1 hour, i.e. 1.2 mg followed by 0.6 mg in 1 hour). Both colchicine regimens were significantly more effective than placebo, with 32.7% responders in the high-dose group, 37.8% responders in the low-dose group, and 15.5% responders in the placebo group (P = 0.034 and P = 0.005, respectively, versus placebo). The results at the primary 24-hour end point demonstrate superior safety of low-dose colchicine, without loss of efficacy, relative to high-dose colchicine for early acute gout flare (self-administered within 12 hours of flare onset). The pharmacokinetic analysis performed in this study showed that the colchicine plasma concentration was decreased substantially from about 12 hours after administration in healthy volunteers.
Colchicine prophylaxis (0.6 mg twice daily) during initiation of allopurinol for chronic gouty arthritis reduced the frequency and severity of acute flares, and reduced the likelihood of recurrent flares. Treatment may be continued for up to 6 months, based on clinical data. Prospective randomized controlled trials are needed to further evaluate flare prophylaxis for up to 6 months, after 6 months, and over time.
The mechanism of action of colchicine in the treatment of gout is not clearly understood. Colchicine is considered to act against the inflammatory response to urate crystals, by possibly inhibiting the migration of granulocytes into the inflamed area. Other properties of colchicine, such as interaction with the microtubules, could also contribute to the operation. Onset of action is approximately 12 hours after oral administration and is maximal after 1 to 2 days.5.2 Pharmacokinetic properties
Colchicine is rapidly and almost completely absorbed after oral administration. Maximum plasma concentrations are met usually after 30 to 120 minutes. The terminal half-life is 3 to 10 hours. Plasma protein binding is approximately 30%. Colchicine is partially metabolised in the liver and then in part via the bile. It accumulates in leucocytes. Colchicine is largely excreted (80%) in unchanged form and as metabolites in the faeces. 10-20% is excreted in the urine.
Renal impairment
Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Total body clearance of colchicine was reduced by 75% in patients with end-stage renal disease undergoing dialysis.
The influence of renal impairment on the pharmacokinetics of colchicine was assessed in a study in patients with familial Mediterranean fever (FMF), 5 women and 4 men, with (n=4) and without (n=5) renal impairment. The mean age was 30 years (range 19-42 years). All 5 patients with renal impairment had biopsy-proven amyloidosis; 4 were on routine haemodialysis and 1 had a serum creatinine CL of 15 ml/min. They could therefore be classified as having severe renal impairment. Subjects received 1 mg colchicine except for 1 subject with cirrhosis who received 500 micrograms. A 4-fold decrease in colchicine CL was observed in subjects with renal impairment compared to those with normal renal function (0.168 ± 0.063 l/h/kg vs. 0.727 ± 0.110 l/h/kg). The terminal half-life was 18.8 ± 1.2 h for subjects with severe renal impairment and 4.4 ± 1.0 h for those with normal renal function. The volume of distribution was similar between groups. The patient with cirrhosis had a 10-fold lower CL compared to the subjects with normal renal function.
\*Paediatric population\*
No pharmacokinetics data are available in children.5.3 Preclinical safety data
Genotoxicity
In one study, a bacterial test indicated that colchicine has a slight mutagenic effect.
However, two other bacterial tests and a test in \*Drosophila melanogaster\* found that colchicine was not mutagenic.
Tests have shown that colchicine induces chromosomal aberrations and micronuclei, and causes some DNA damage.
Teratogenicity
Tests in animals have shown that colchicine is teratogenic.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Lactose monohydrate
Pregelatinized starch
Purified talc, E 553b
Stearic acid, E 5706.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years for OPA/Al/PVC-Alu blister pack.
30 months for PVC-Alu blister pack.6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light.6.5 Nature and contents of container
Blister packs of OPA/Al/PVC with Al lidding foil, containing 10 or 14 tablets.
Blister packs of white opaque PVC with Al lidding foil, containing 10 or 14 tablets.
Blister of 10 tablets in packs of 10, 20, 30, 40, 50, 60, 90, or 100 tablets.
Blister of 14 tablets in packs of 14, 28, 56, 84, or 112 tablets.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
For patients where oral administration of a tablet is not possible, administration can be achieved by tablet solubilisation, and subsequent administration as an oral dispersion, or via a nasogastric tube or a percutaneous endoscopic gastrostomy (PEG) tube. Such dispersions should be administered as suggested in the following recommendations. For dosage see section 4.2.
Administration as an oral dispersion:
The dose may be dispersed in a medicines cup containing between 10 ml – 30 ml of water. Add a single tablet to the volume of water and stir for five seconds using a suitable stirring device e.g. spoon. Allow to stand for about 2 minutes and stir for five seconds, and 5 minutes after tablet addition, stir for a further five seconds and administer the entire volume orally immediately. To ensure complete administration of the dose, the cup should be rinsed with a further quantity of water, 10 ml – 30 ml, and administered orally.
Alternatively, the dose may be administered via a 5 ml oral dosing syringe (enteral medicines dispenser). Remove the plunger and insert one tablet into the device. Replace the plunger and depress until in contact with the tablet. Draw up 5 ml of water into the device and expel any residual air. Disperse the tablet by rotation of the dispenser in a vertical axis, five times, allow to stand for 5 minutes, repeat the five rotations, allow again to stand for five minutes, repeat the five rotations.
Administer the required dose immediately. To ensure complete dosage administration, a further 5 ml quantity of water should be drawn up into the dosing syringe and administered immediately.
Administration via a nasogastric or percutaneous endoscopic gastrostomy (PEG) Tube:
Tubes made of polyurethane, polyvinylchloride, or silicone are suitable for use. There is no data available on tubes made of latex. Therefore, latex tubes should not be used.
Use a 60 ml syringe and remove the plunger, insert one tablet in the syringe barrel, and replace the plunger, depressing until just clear of tablet.
Draw 30 ml of water into the syringe, and manually shake for 30 seconds. Shake for another 30 seconds after 5 minutes, 10 minutes, and 15 minutes post water draw up. Administer the dispersed dose, via nasogastric or PEG tube immediately after preparation. Following administration, the dosing syringe should be disconnected and flushed with a further quantity, 10 ml – 30 ml of water, which should also be administered via tube to ensure complete dosage administration. In cases of fluid restriction, the initial volume for dispersion may be reduced to a minimum of 10 ml.
- Instruction Content
- ## Composition
Each tablet contains 500 micrograms of colchicine (as colchicine sesquihydrate).
Excipient(s) with known effect: each tablet contains 46 mg lactose monohydrate equivalent to 43.7 mg of lactose anhydrous (see section 4.4).
For the full list of excipients, see 6.1.
## Pharmaceutical Form
Tablet - oral use.
White to off-white coloured, circular biconvex uncoated tablet with “C5” debossed on one side and plain on the other side with diameter of 5.5 mm.
## Clinical Particulars
4.1 Therapeutic indications
\*Adults\*
• Treatment of acute gout.
• Prophylaxis of gout attack during initiation of therapy with allopurinol and uricosuric drugs.
\*\*Paediatric Population:\*\*
Colchicine is indicated in Familial Mediterranean Fever for prophylaxis of attacks and prevention of amyloidosis.4.2 Posology and method of administration
Posology
\*Adults\*
\*Treatment of acute gout attack:\*
1 mg (2 tablets) to start followed by 500 micrograms (1 tablet) after1 hour.
No further tablets should be taken for 12 hours.
After 12 hours, treatment can resume if necessary with a maximum dose of500 micrograms (1 tablet) every 8 hours until symptoms are relieved.\*.\* The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken.
No more than6 mg (12 tablets) should be taken as a course of treatment.
After completion of a course, another course should not be started for at least three days (72 hours).
\*Prophylaxis of gout attack during initiation of therapy with allopurinol and uricosuric drugs:\*
500 micrograms twice daily.
The treatment duration should be decided after factors such as flare frequency, gout duration and the presence and size of tophi have been assessed.
\*Patients with renal impairment\*
Use with caution in patients with mild renal impairment. For patients with moderate renal impairment, reduce dose or increase interval between doses. Such patients should be carefully monitored for adverse effects of colchicine (see also section 5.2).
For patients with severe renal impairment, see section 4.3.
\*Patients with hepatic impairment\*
Use with caution in patients with mild/moderate hepatic impairment. Such patients should be carefully monitored for adverse effects of colchicine.
For patients with severe hepatic impairment, see section 4.3.
\*Paediatric population\*
Familial Mediterranean fever.
For paediatric use, colchicine should only be prescribed under the supervision of a medical specialist with the necessary knowledge and experience.
A starting dose should be administered orally based on age:
0.5 mg / day in children less than 5 years of age (1 tablet);
1 mg / day in children from 5 to 10 years of age (2 tablets);
1.5 mg / day in children over 10 years (3 tablets).
The dose could be given as a single dose or doses higher than 1 mg / day could be divided and given twice daily.
Colchicine dosage should be increased in a stepwise fashion (e.g., 0.25mg/step) up to a maximum of 2mg/day (four tablets a day) to control disease in patients who do not clinically respond to the standard dosage. Any increase of the daily dose should be monitored closely for adverse effects. In children with amyloid nephropathy, higher daily doses up to 2mg/day might be needed. Careful monitoring is needed in the presence of impaired renal or liver function. For these patients, the starting dose should be reduced by 50% (e.g. ≤ 1mg/day).
\*Elderly\*
Use with caution.
Method of Administration
For Oral administration
Tablets should be swallowed whole with a glass of water.
In certain circumstances, it may not be possible to administer the tablets orally, please refer to recommendations in section 6.6 for administration as an oral dispersion. These recommendations are also suitable for administration via nasogastric tube or percutaneous endoscopic gastrostomy (PEG) tube.4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• Patients with blood dyscrasias
• Pregnancy
• Breastfeeding
• Women of childbearing potential unless using effective contraceptive measures
• Patients with severe renal impairment
• Patients with severe hepatic impairment
• Colchicine should not be used in patients undergoing haemodialysis since it cannot be removed by dialysis or exchange transfusion.
• Colchicine is contraindicated in patients with renal or hepatic impairment who are taking a P-glycoprotein (P-gp) inhibitor or a strong CYP3A4 inhibitor (see section 4.5)4.4 Special warnings and precautions for use
Colchicine is potentially toxic so it is important not to exceed the dose prescribed by a physician with the necessary knowledge and experience.
Colchicine has a narrow therapeutic window. The administration should be discontinued if toxic symptoms such as nausea, vomiting, abdominal pain, diarrhoea occur.
Colchicine may cause severe bone marrow depression (agranulocytosis, aplastic anaemia, thrombocytopenia). The change in blood counts may be gradual or very sudden. Aplastic anaemia in particular has a high mortality rate. Periodic checks of the blood picture are essential.
If patients develop signs or symptoms that could indicate a blood cell dyscrasia, such as fever, stomatitis, sore throat, prolonged bleeding, bruising or skin disorders, treatment with colchicine should be immediately discontinued and a full haematological investigation should be conducted straight away.
Caution is advised in case of:
• liver or renal impairment• cardiovascular disease• gastrointestinal disorders• elderly and debilitated patients• patients with abnormalities in blood counts
Patients with liver or renal impairment should be carefully monitored for adverse effects of colchicine (see section 5.2).
Co-administration with P-gp inhibitors and/or moderate or strong CYP3A4 inhibitors will increase the exposure to colchicine, which may lead to colchicine-induced toxicity including fatalities. If treatment with a P-gp inhibitor or a moderate or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, a reduction in colchicine dosage or interruption of colchicine treatment is recommended (see section 4.5).
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction
Colchicine is a substrate for both CYP3A4 and the transport protein P-gp. In the presence of CYP3A4 or P-gp inhibitors, the concentrations of colchicine in the blood increase. Toxicity, including fatal cases, have been reported during concurrent use of CYP3A4 or P-gp inhibitors such as macrolides (clarithromycin and erythromycin), ciclosporin, ketoconazole, itraconazole, voriconazole, HIV protease inhibitors, calcium channel blockers (verapamil and diltiazem) and disulfiram (see section 4.4).
Colchicine is contraindicated in patients with renal or hepatic impairment who are taking a P-gp inhibitor (e.g. ciclosporin, verapamil or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, atazanavir, indinavir, clarithromycin, telithromycin, itraconazole or ketoconazole) (see section 4.3).
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with a P-gp inhibitor or strong CYP3A4 inhibitor is required (see section 4.4).
A 4-fold reduction in colchicine dosage is recommended when co-administered with a P-gp inhibitor and/or a strong CYP3A4 inhibitor. A 2-fold reduction in colchicine dosage is recommended when co-administered with a moderate CYP3A4 inhibitor.
The magnitude of interactions with strong and moderate CYP3A4 inhibitors as well as with P-gp inhibitors from performed \*in vivo\* studies is summarised in the table below:
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Single dose of 0.6 mg colchicine without or with:\*\* | \*\*Number of subjects\*\* | \*\*% change in colchicine pharmacokinetic parameters\*\* | | \*\*Guidance for dose reduction:\*\* |
| \*\*Cmax\*\* | \*\*AUCo-t\*\* |
| \*\*Strong CYP3A4 inhibitors\*\* Clarithromycin 250 mg twice daily for 7 days Ketoconazole 200 mg twice daily for 5 days Ritonavir 100 mg twice daily for 5 days | N=23 N=24 N=18 | 297 190 267 | 339 287 345 | 4-fold Acute gout regimen to be repeated no earlier than 3 days. |
| \*\*Moderate CYP3A4 inhibitors\*\* Verapamil ER 240 mg once daily for 5 days Diltiazem ER 240 mg once daily for 7 days Grapefruit juice 240 ml twice daily for 4 days | N=24 N=20 N=21 | 130 129 93 | 188 177 95 | 2-fold Acute gout regimen to be repeated no earlier than 3 days. |
| \*\*Potent P-gp inhibitors\*\* Cyclosporin 100 mg single dose | N=23 | 324 | 317 | 4-fold Acute gout regimen to be repeated no earlier than 3 days. |
Given the nature of the side effects, caution is advised with concomitant administration of drugs that can affect the blood count or have a negative effect on hepatic and/or renal function.
In addition, substances such as cimetidine and tolbutamide reduce metabolism of colchicine and thus plasma levels of colchicine increase.
Grapefruit juice may increase plasma levels of colchicine. Grapefruit juice should therefore not be taken together with colchicine.
Reversible malabsorption of cyanocobalamin (vitamin B12) may be induced by an altered function of the intestinal mucosa.
The risk of myopathy and rhabdomyolysis is increased by a combination of colchicine with statins, fibrates, ciclosporin or digoxin.4.6 Fertility, pregnancy and lactation
Fertility
Colchicine administration in animals induces significant reductions in fertility.
Pregnancy
Colchicine is genotoxic in vitro and in vivo, and is teratogenic in animal studies (see section 5.3). Colchicine is therefore contraindicated in pregnancy (see section 4.3).
Women of childbearing potential have to use effective contraception during treatment.
Women should be advised not to become pregnant whilst taking Colchicine and for nine months following the cessation of therapy and should use barrier or other non-hormonal contraceptive methods if sexually active. Premenopausal patients must be carefully examined before treatment to exclude pregnancy. Women should be appraised of the potential risks to the foetus, should they become pregnant whilst taking medicine or within nine months of cessation of therapy.
Breastfeeding
Colchicine is excreted in breast milk. Therefore, use of colchicine is contraindicated in women who are breastfeeding (see section 4.3).4.7 Effects on ability to drive and use machines
No details are available regarding the influence of colchicine on the ability to drive and use machines. However, the possibility of drowsiness and dizziness should be taken into account.4.8 Undesirable effects
The following adverse reactions have been observed.
The frequencies are listed under one of the following classifications:
Very common > 1/10
Common > 1/100 and < 1/10Uncommon > 1/1,000 and < 1/100Rare>1/10,000 and < 1/1,000Very rare < 1/10,000
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
\*Not known\*: bone marrow depression with agranulocytosis, aplastic anaemia and thrombocytopenia.
Nervous system disorders
\*Not known\*: peripheral neuritis, neuropathy.
Gastrointestinal system disorders
\*Common\*: abdominal pain, nausea, vomiting and diarrhoea.
\*Not known\*: gastrointestinal haemorrhage.
Hepatobiliary disorders
\*Not known\*: Hepatotoxicity
Skin and subcutaneous tissue disorders
\*Not known\*: alopecia, rash.
Musculoskeletal and connective tissue disorders
\*Not known\*: myopathy and rhabdomyolysis.
Renal and urinary disorders
\*Not known\*: renal damage.
Reproductive system and breast disorders
\*Not known\*: amenorrhoea, dysmenorrhoea, oligospermia, azoospermia.
\*\*Reporting of suspected adverse reactions:\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Colchicine has a narrow therapeutic window and is extremely toxic in overdose. Patients at particular risk of toxicity are those with renal or hepatic impairment, gastro-intestinal or cardiac disease and patients at extremes of age.
Following colchicine overdose, all patients, even in the absence of early symptoms, should be referred for immediate medical assessment.
\*Clinical:\*
Symptoms of acute overdosage may be delayed (3 hours on average): nausea, vomiting, abdominal pain, haemorrhagic gastroenteritis, volume depletion, electrolyte abnormalities, leukocytosis, and hypotension in severe cases. The second phase with life threatening complications develops 24 to 72 hours after drug administration: multisystem organ dysfunction, acute renal failure, confusion, coma, ascending peripheral motor and sensory neuropathy, myocardial depression, pancytopenia, dysrhythmias, respiratory failure, consumption coagulopathy. Death is usually a result of respiratory depression and cardiovascular collapse. If the patient survives, recovery may be accompanied by rebound leukocytosis and reversible alopecia starting about one week after the initial ingestion.
\*Treatment:\*
No antidote is available.
Elimination of toxins by gastric lavage within one hour of acute poisoning.
Consider oral activated charcoal in adults who have ingested more than 0.1mg/kg bodyweight within 1 hour of presentation and in children who have ingested any amount within 1 hour of presentation. Haemodialysis has no efficacy (high apparent distribution volume).
Close clinical and biological monitoring in hospital environment.
Symptomatic and supportive treatment: control of respiration, maintenance of blood pressure and circulation, correction of fluid and electrolytes imbalance.
The lethal dose varies widely (7 - 65 mg single dose) for adults but is generally about 20 mg.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: drugs for gout, with no effect on uric acid metabolism. ATC code: M04AC01
In the AGREE (Acute Gout Flare Receiving Colchicine Evaluation) study low- and high-dose colchicine were compared using a randomized, placebo-controlled design. The high-dose prolonged colchicine regimen (4.8 mg total over 6 hours) was compared with a placebo and a low-dose abbreviated regimen (1.8 mg total over 1 hour, i.e. 1.2 mg followed by 0.6 mg in 1 hour). Both colchicine regimens were significantly more effective than placebo, with 32.7% responders in the high-dose group, 37.8% responders in the low-dose group, and 15.5% responders in the placebo group (P = 0.034 and P = 0.005, respectively, versus placebo). The results at the primary 24-hour end point demonstrate superior safety of low-dose colchicine, without loss of efficacy, relative to high-dose colchicine for early acute gout flare (self-administered within 12 hours of flare onset). The pharmacokinetic analysis performed in this study showed that the colchicine plasma concentration was decreased substantially from about 12 hours after administration in healthy volunteers.
Colchicine prophylaxis (0.6 mg twice daily) during initiation of allopurinol for chronic gouty arthritis reduced the frequency and severity of acute flares, and reduced the likelihood of recurrent flares. Treatment may be continued for up to 6 months, based on clinical data. Prospective randomized controlled trials are needed to further evaluate flare prophylaxis for up to 6 months, after 6 months, and over time.
The mechanism of action of colchicine in the treatment of gout is not clearly understood. Colchicine is considered to act against the inflammatory response to urate crystals, by possibly inhibiting the migration of granulocytes into the inflamed area. Other properties of colchicine, such as interaction with the microtubules, could also contribute to the operation. Onset of action is approximately 12 hours after oral administration and is maximal after 1 to 2 days.5.2 Pharmacokinetic properties
Colchicine is rapidly and almost completely absorbed after oral administration. Maximum plasma concentrations are met usually after 30 to 120 minutes. The terminal half-life is 3 to 10 hours. Plasma protein binding is approximately 30%. Colchicine is partially metabolised in the liver and then in part via the bile. It accumulates in leucocytes. Colchicine is largely excreted (80%) in unchanged form and as metabolites in the faeces. 10-20% is excreted in the urine.
Renal impairment
Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Total body clearance of colchicine was reduced by 75% in patients with end-stage renal disease undergoing dialysis.
The influence of renal impairment on the pharmacokinetics of colchicine was assessed in a study in patients with familial Mediterranean fever (FMF), 5 women and 4 men, with (n=4) and without (n=5) renal impairment. The mean age was 30 years (range 19-42 years). All 5 patients with renal impairment had biopsy-proven amyloidosis; 4 were on routine haemodialysis and 1 had a serum creatinine CL of 15 ml/min. They could therefore be classified as having severe renal impairment. Subjects received 1 mg colchicine except for 1 subject with cirrhosis who received 500 micrograms. A 4-fold decrease in colchicine CL was observed in subjects with renal impairment compared to those with normal renal function (0.168 ± 0.063 l/h/kg vs. 0.727 ± 0.110 l/h/kg). The terminal half-life was 18.8 ± 1.2 h for subjects with severe renal impairment and 4.4 ± 1.0 h for those with normal renal function. The volume of distribution was similar between groups. The patient with cirrhosis had a 10-fold lower CL compared to the subjects with normal renal function.
\*Paediatric population\*
No pharmacokinetics data are available in children.5.3 Preclinical safety data
Genotoxicity
In one study, a bacterial test indicated that colchicine has a slight mutagenic effect.
However, two other bacterial tests and a test in \*Drosophila melanogaster\* found that colchicine was not mutagenic.
Tests have shown that colchicine induces chromosomal aberrations and micronuclei, and causes some DNA damage.
Teratogenicity
Tests in animals have shown that colchicine is teratogenic.
## Pharmaceutical Particulars
6.1 List of excipients
Lactose monohydrate
Pregelatinized starch
Purified talc, E 553b
Stearic acid, E 5706.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years for OPA/Al/PVC-Alu blister pack.
30 months for PVC-Alu blister pack.6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light.6.5 Nature and contents of container
Blister packs of OPA/Al/PVC with Al lidding foil, containing 10 or 14 tablets.
Blister packs of white opaque PVC with Al lidding foil, containing 10 or 14 tablets.
Blister of 10 tablets in packs of 10, 20, 30, 40, 50, 60, 90, or 100 tablets.
Blister of 14 tablets in packs of 14, 28, 56, 84, or 112 tablets.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
For patients where oral administration of a tablet is not possible, administration can be achieved by tablet solubilisation, and subsequent administration as an oral dispersion, or via a nasogastric tube or a percutaneous endoscopic gastrostomy (PEG) tube. Such dispersions should be administered as suggested in the following recommendations. For dosage see section 4.2.
Administration as an oral dispersion:
The dose may be dispersed in a medicines cup containing between 10 ml – 30 ml of water. Add a single tablet to the volume of water and stir for five seconds using a suitable stirring device e.g. spoon. Allow to stand for about 2 minutes and stir for five seconds, and 5 minutes after tablet addition, stir for a further five seconds and administer the entire volume orally immediately. To ensure complete administration of the dose, the cup should be rinsed with a further quantity of water, 10 ml – 30 ml, and administered orally.
Alternatively, the dose may be administered via a 5 ml oral dosing syringe (enteral medicines dispenser). Remove the plunger and insert one tablet into the device. Replace the plunger and depress until in contact with the tablet. Draw up 5 ml of water into the device and expel any residual air. Disperse the tablet by rotation of the dispenser in a vertical axis, five times, allow to stand for 5 minutes, repeat the five rotations, allow again to stand for five minutes, repeat the five rotations.
Administer the required dose immediately. To ensure complete dosage administration, a further 5 ml quantity of water should be drawn up into the dosing syringe and administered immediately.
Administration via a nasogastric or percutaneous endoscopic gastrostomy (PEG) Tube:
Tubes made of polyurethane, polyvinylchloride, or silicone are suitable for use. There is no data available on tubes made of latex. Therefore, latex tubes should not be used.
Use a 60 ml syringe and remove the plunger, insert one tablet in the syringe barrel, and replace the plunger, depressing until just clear of tablet.
Draw 30 ml of water into the syringe, and manually shake for 30 seconds. Shake for another 30 seconds after 5 minutes, 10 minutes, and 15 minutes post water draw up. Administer the dispersed dose, via nasogastric or PEG tube immediately after preparation. Following administration, the dosing syringe should be disconnected and flushed with a further quantity, 10 ml – 30 ml of water, which should also be administered via tube to ensure complete dosage administration. In cases of fluid restriction, the initial volume for dispersion may be reduced to a minimum of 10 ml.
- Company Detail Path
- /organization/morningside-healthcare-ltd
